Non-Animal Alternative Testing Market By Technology (Cell Culture, High Throughput, Molecular Imaging, OMIC Technology), By Method (Cellular Assay, Biochemical Assay, In-silico, Ex-vivo), By End User (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemicals Industry, Food Industry): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global non-animal alternative testing market is envisioned to garner $29,390.3 million by 2030, growing from $9,806.6 million in 2021 at a CAGR of 13.48% from 2022 to 2030.
Animal testing has been common across generations to establish whether particular chemicals are safe for use by humans and/or the environment. However, this primary method raises a number of issues about the animals involved and is also widely seen as inhumane. This forced medical professionals and researchers everywhere to concentrate their efforts and adopt fresh approaches to understand disease pathophysiology in people. Recent experiments are guiding scientists toward non-animal testing and disease study techniques that are much more applicable to humans.
A large increase in the demand for pharmaceuticals and treatments among people as a result of increasing prevalence of various illnesses around the world is the primary reason driving expansion of the global non-animal alternative testing market. Additionally, increased focus of market players on the development of novel products such as artificial organs, to meet the rising demand for cutting-edge drug testing solutions for a variety of illnesses, such as diabetes, is anticipated to open doors for the market growth in the anticipated period. However, it is anticipated that throughout the projection period, lack of awareness among drug developers regarding the use and advantages of non-animal alternative testing is projected to restrain the market growth.
It has been demonstrated that the emergence of the COVID-19 pandemic had a positive impact on the development of the non-animal alternative testing industry. As the COVID-19 pandemic has had such a terrible impact on people's health and welfare globally, patients now take extra care and precautions to stay safe from viral infections. Due to the high rate of coronavirus transmission and prevalence of serious symptoms, many researchers have forbidden themselves from working in a wet laboratory and making any sort of contact with either humans or animals during pre-clinical testing of the drugs. As a result, the use of less invasive testing techniques has increased such as microarrays, which do not involve using animals.
The key players profiled in this report include VITROCELL Systems GmbH, Evotec SE, Biovit, MB Research Laboratories, Emulate, Inc., TARA Biosystems, Inc., Bio-Rad Laboratories, Inc., Abbott, Hurel Corporation, and TissUse GmbH.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the non-animal alternative testing market analysis from 2021 to 2030 to identify the prevailing non-animal alternative testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the non-animal alternative testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global non-animal alternative testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
Cell Culture Technology
High Throughput Technology
Molecular Imaging
Omic Technology
By Method
Cellular Assay
Biochemical Assay
In Silico
Ex-Vivo
By End-user
Pharmaceutical Industry
Cosmetics & Household Products
Diagnostics
Chemical Industry
Food Industry
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
United Arab Emirates
South Africa
Rest of LAMEA
List of Key Players Profiled in the Report
VITROCELL Systems GmbH
Evotec SE
Biovit
MB Research Laboratories
Emulate, Inc.
TARA Biosystems, Inc.
Bio-Rad Laboratories, Inc.
Abbott
Hurel Corporation
TissUse GmbH
Key Market Segments
By Technology
Cell Culture
High Throughput
Molecular Imaging
OMIC Technology
By Method
Cellular Assay
Biochemical Assay
In-silico
Ex-vivo
By End User
Pharmaceutical Industry
Cosmetics Household Products
Diagnostics
Chemicals Industry
Food Industry
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
VITROCELL Systems GmbH
Evotec SE
Biovit
MB Research Laboratories
Emulate, Inc.
TARA Biosystems, Inc.
Bio-Rad Laboratories, Inc.
Abbott
Hurel Corporation
TissUse GmbH
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Regulatory Guidelines
- 3.8.Value Chain Analysis
- 3.9.Market Share Analysis
- 3.10.Key Regulation Analysis
- 3.11.Patent Landscape
- CHAPTER 4: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Cell Culture
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 High Throughput
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Molecular Imaging
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 OMIC Technology
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Cellular Assay
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Biochemical Assay
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 In-silico
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Ex-vivo
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- CHAPTER 6: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Pharmaceutical Industry
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Cosmetics & Household Products
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Diagnostics
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Chemicals Industry
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- 6.6 Food Industry
- 6.6.1 Key market trends, growth factors and opportunities
- 6.6.2 Market size and forecast, by region
- 6.6.3 Market analysis by country
- CHAPTER 7: NON-ANIMAL ALTERNATIVE TESTING MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Technology
- 7.2.3 North America Market size and forecast, by Method
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Technology
- 7.2.5.1.2 Market size and forecast, by Method
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Technology
- 7.2.5.2.2 Market size and forecast, by Method
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Technology
- 7.2.5.3.2 Market size and forecast, by Method
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Technology
- 7.3.3 Europe Market size and forecast, by Method
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Technology
- 7.3.5.1.2 Market size and forecast, by Method
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 United Kingdom
- 7.3.5.2.1 Market size and forecast, by Technology
- 7.3.5.2.2 Market size and forecast, by Method
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 France
- 7.3.5.3.1 Market size and forecast, by Technology
- 7.3.5.3.2 Market size and forecast, by Method
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Spain
- 7.3.5.4.1 Market size and forecast, by Technology
- 7.3.5.4.2 Market size and forecast, by Method
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Italy
- 7.3.5.5.1 Market size and forecast, by Technology
- 7.3.5.5.2 Market size and forecast, by Method
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Technology
- 7.3.5.6.2 Market size and forecast, by Method
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Technology
- 7.4.3 Asia-Pacific Market size and forecast, by Method
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Technology
- 7.4.5.1.2 Market size and forecast, by Method
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Technology
- 7.4.5.2.2 Market size and forecast, by Method
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Technology
- 7.4.5.3.2 Market size and forecast, by Method
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 South Korea
- 7.4.5.4.1 Market size and forecast, by Technology
- 7.4.5.4.2 Market size and forecast, by Method
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 Australia
- 7.4.5.5.1 Market size and forecast, by Technology
- 7.4.5.5.2 Market size and forecast, by Method
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Technology
- 7.4.5.6.2 Market size and forecast, by Method
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Technology
- 7.5.3 LAMEA Market size and forecast, by Method
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Technology
- 7.5.5.1.2 Market size and forecast, by Method
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Technology
- 7.5.5.2.2 Market size and forecast, by Method
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 UAE
- 7.5.5.3.1 Market size and forecast, by Technology
- 7.5.5.3.2 Market size and forecast, by Method
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 South Africa
- 7.5.5.4.1 Market size and forecast, by Technology
- 7.5.5.4.2 Market size and forecast, by Method
- 7.5.5.4.3 Market size and forecast, by End User
- 7.5.5.5 Rest of LAMEA
- 7.5.5.5.1 Market size and forecast, by Technology
- 7.5.5.5.2 Market size and forecast, by Method
- 7.5.5.5.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 VITROCELL Systems GmbH
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Evotec SE
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Biovit
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 MB Research Laboratories
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Emulate, Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 TARA Biosystems, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Bio-Rad Laboratories, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Abbott
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Hurel Corporation
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 TissUse GmbH
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 2. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR CELL CULTURE, BY REGION, 2021-2030 ($MILLION)
- TABLE 3. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR CELL CULTURE, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 4. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR HIGH THROUGHPUT, BY REGION, 2021-2030 ($MILLION)
- TABLE 5. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR HIGH THROUGHPUT, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 6. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR MOLECULAR IMAGING, BY REGION, 2021-2030 ($MILLION)
- TABLE 7. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR MOLECULAR IMAGING, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 8. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR OMIC TECHNOLOGY, BY REGION, 2021-2030 ($MILLION)
- TABLE 9. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR OMIC TECHNOLOGY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 10. GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 11. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR CELLULAR ASSAY, BY REGION, 2021-2030 ($MILLION)
- TABLE 12. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR CELLULAR ASSAY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 13. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR BIOCHEMICAL ASSAY, BY REGION, 2021-2030 ($MILLION)
- TABLE 14. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR BIOCHEMICAL ASSAY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 15. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR IN-SILICO, BY REGION, 2021-2030 ($MILLION)
- TABLE 16. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR IN-SILICO, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 17. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR EX-VIVO, BY REGION, 2021-2030 ($MILLION)
- TABLE 18. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR EX-VIVO, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 19. GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 20. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR PHARMACEUTICAL INDUSTRY, BY REGION, 2021-2030 ($MILLION)
- TABLE 21. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 22. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR COSMETICS & HOUSEHOLD PRODUCTS, BY REGION, 2021-2030 ($MILLION)
- TABLE 23. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR COSMETICS & HOUSEHOLD PRODUCTS, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 24. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR DIAGNOSTICS, BY REGION, 2021-2030 ($MILLION)
- TABLE 25. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 26. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR CHEMICALS INDUSTRY, BY REGION, 2021-2030 ($MILLION)
- TABLE 27. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR CHEMICALS INDUSTRY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 28. NON-ANIMAL ALTERNATIVE TESTING MARKET SIZE, FOR FOOD INDUSTRY, BY REGION, 2021-2030 ($MILLION)
- TABLE 29. NON-ANIMAL ALTERNATIVE TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 30. NON-ANIMAL ALTERNATIVE TESTING MARKET, BY REGION, 2021-2030 ($MILLION)
- TABLE 31. NORTH AMERICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 32. NORTH AMERICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 33. NORTH AMERICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 34. NORTH AMERICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 35. U.S. NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 36. U.S. NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 37. U.S. NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 38. CANADA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 39. CANADA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 40. CANADA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 41. MEXICO NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 42. MEXICO NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 43. MEXICO NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 44. EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 45. EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 46. EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 47. EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 48. GERMANY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 49. GERMANY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 50. GERMANY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 51. UNITED KINGDOM NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 52. UNITED KINGDOM NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 53. UNITED KINGDOM NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 54. FRANCE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 55. FRANCE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 56. FRANCE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 57. SPAIN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 58. SPAIN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 59. SPAIN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 60. ITALY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 61. ITALY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 62. ITALY NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 63. REST OF EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 64. REST OF EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 65. REST OF EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 66. ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 67. ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 68. ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 69. ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 70. CHINA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 71. CHINA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 72. CHINA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 73. JAPAN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 74. JAPAN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 75. JAPAN NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 76. INDIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 77. INDIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 78. INDIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 79. SOUTH KOREA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 80. SOUTH KOREA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 81. SOUTH KOREA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 82. AUSTRALIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 83. AUSTRALIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 84. AUSTRALIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 88. LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 89. LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 90. LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 91. LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY COUNTRY, 2021-2030 ($MILLION)
- TABLE 92. BRAZIL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 93. BRAZIL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 94. BRAZIL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 95. SAUDI ARABIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 96. SAUDI ARABIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 97. SAUDI ARABIA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 98. UAE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 99. UAE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 100. UAE NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 101. SOUTH AFRICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 102. SOUTH AFRICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 103. SOUTH AFRICA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 104. REST OF LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY, 2021-2030 ($MILLION)
- TABLE 105. REST OF LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD, 2021-2030 ($MILLION)
- TABLE 106. REST OF LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET, BY END USER, 2021-2030 ($MILLION)
- TABLE 107.VITROCELL SYSTEMS GMBH: COMPANY SNAPSHOT
- TABLE 108.VITROCELL SYSTEMS GMBH: OPERATING SEGMENTS
- TABLE 109.VITROCELL SYSTEMS GMBH: PRODUCT PORTFOLIO
- TABLE 110.VITROCELL SYSTEMS GMBH: NET SALES,
- TABLE 111.VITROCELL SYSTEMS GMBH: KEY STRATERGIES
- TABLE 112.EVOTEC SE: COMPANY SNAPSHOT
- TABLE 113.EVOTEC SE: OPERATING SEGMENTS
- TABLE 114.EVOTEC SE: PRODUCT PORTFOLIO
- TABLE 115.EVOTEC SE: NET SALES,
- TABLE 116.EVOTEC SE: KEY STRATERGIES
- TABLE 117.BIOVIT: COMPANY SNAPSHOT
- TABLE 118.BIOVIT: OPERATING SEGMENTS
- TABLE 119.BIOVIT: PRODUCT PORTFOLIO
- TABLE 120.BIOVIT: NET SALES,
- TABLE 121.BIOVIT: KEY STRATERGIES
- TABLE 122.MB RESEARCH LABORATORIES: COMPANY SNAPSHOT
- TABLE 123.MB RESEARCH LABORATORIES: OPERATING SEGMENTS
- TABLE 124.MB RESEARCH LABORATORIES: PRODUCT PORTFOLIO
- TABLE 125.MB RESEARCH LABORATORIES: NET SALES,
- TABLE 126.MB RESEARCH LABORATORIES: KEY STRATERGIES
- TABLE 127.EMULATE, INC.: COMPANY SNAPSHOT
- TABLE 128.EMULATE, INC.: OPERATING SEGMENTS
- TABLE 129.EMULATE, INC.: PRODUCT PORTFOLIO
- TABLE 130.EMULATE, INC.: NET SALES,
- TABLE 131.EMULATE, INC.: KEY STRATERGIES
- TABLE 132.TARA BIOSYSTEMS, INC.: COMPANY SNAPSHOT
- TABLE 133.TARA BIOSYSTEMS, INC.: OPERATING SEGMENTS
- TABLE 134.TARA BIOSYSTEMS, INC.: PRODUCT PORTFOLIO
- TABLE 135.TARA BIOSYSTEMS, INC.: NET SALES,
- TABLE 136.TARA BIOSYSTEMS, INC.: KEY STRATERGIES
- TABLE 137.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
- TABLE 138.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
- TABLE 139.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
- TABLE 140.BIO-RAD LABORATORIES, INC.: NET SALES,
- TABLE 141.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
- TABLE 142.ABBOTT: COMPANY SNAPSHOT
- TABLE 143.ABBOTT: OPERATING SEGMENTS
- TABLE 144.ABBOTT: PRODUCT PORTFOLIO
- TABLE 145.ABBOTT: NET SALES,
- TABLE 146.ABBOTT: KEY STRATERGIES
- TABLE 147.HUREL CORPORATION: COMPANY SNAPSHOT
- TABLE 148.HUREL CORPORATION: OPERATING SEGMENTS
- TABLE 149.HUREL CORPORATION: PRODUCT PORTFOLIO
- TABLE 150.HUREL CORPORATION: NET SALES,
- TABLE 151.HUREL CORPORATION: KEY STRATERGIES
- TABLE 152.TISSUSE GMBH: COMPANY SNAPSHOT
- TABLE 153.TISSUSE GMBH: OPERATING SEGMENTS
- TABLE 154.TISSUSE GMBH: PRODUCT PORTFOLIO
- TABLE 155.TISSUSE GMBH: NET SALES,
- TABLE 156.TISSUSE GMBH: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.NON-ANIMAL ALTERNATIVE TESTING MARKET SEGMENTATION
- FIGURE 2.NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030
- FIGURE 3.NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.NON-ANIMAL ALTERNATIVE TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.REGULATORY GUIDELINES
- FIGURE 13.VALUE CHAIN ANALYSIS
- FIGURE 14.MARKET SHARE ANALYSIS
- FIGURE 15.KEY REGULATION ANALYSIS
- FIGURE 16.PATENT ANALYSIS BY COMPANY
- FIGURE 17.PATENT ANALYSIS BY COUNTRY
- FIGURE 18.NON-ANIMAL ALTERNATIVE TESTING MARKET,BY TECHNOLOGY,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HIGH THROUGHPUT NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF MOLECULAR IMAGING NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OMIC TECHNOLOGY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 23.NON-ANIMAL ALTERNATIVE TESTING MARKET,BY METHOD,2021(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CELLULAR ASSAY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BIOCHEMICAL ASSAY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF IN-SILICO NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF EX-VIVO NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 28.NON-ANIMAL ALTERNATIVE TESTING MARKET,BY END USER,2021(%)
- FIGURE 29.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL INDUSTRY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 30.COMPARATIVE SHARE ANALYSIS OF COSMETICS & HOUSEHOLD PRODUCTS NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 31.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTICS NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 32.COMPARATIVE SHARE ANALYSIS OF CHEMICALS INDUSTRY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 33.COMPARATIVE SHARE ANALYSIS OF FOOD INDUSTRY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030(%)
- FIGURE 34.NON-ANIMAL ALTERNATIVE TESTING MARKET BY REGION,2021
- FIGURE 35.U.S. NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 36.CANADA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 37.MEXICO NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 38.GERMANY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 39.UNITED KINGDOM NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 40.FRANCE NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 41.SPAIN NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 42.ITALY NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 43.REST OF EUROPE NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 44.CHINA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 45.JAPAN NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 46.INDIA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 47.SOUTH KOREA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 48.AUSTRALIA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 49.REST OF ASIA-PACIFIC NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 50.BRAZIL NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 51.SAUDI ARABIA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 52.UAE NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 53.SOUTH AFRICA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 54.REST OF LAMEA NON-ANIMAL ALTERNATIVE TESTING MARKET,2021-2030($MILLION)
- FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 59.COMPETITIVE DASHBOARD
- FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 61.VITROCELL SYSTEMS GMBH.: NET SALES ,($MILLION)
- FIGURE 62.EVOTEC SE.: NET SALES ,($MILLION)
- FIGURE 63.BIOVIT.: NET SALES ,($MILLION)
- FIGURE 64.MB RESEARCH LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 65.EMULATE, INC..: NET SALES ,($MILLION)
- FIGURE 66.TARA BIOSYSTEMS, INC..: NET SALES ,($MILLION)
- FIGURE 67.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
- FIGURE 68.ABBOTT.: NET SALES ,($MILLION)
- FIGURE 69.HUREL CORPORATION.: NET SALES ,($MILLION)
- FIGURE 70.TISSUSE GMBH.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook